TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04087668

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Monitored Anesthesia Care
Description: MAC was induced and maintained via the continuous infusion of propofol AND remifentanil using a target-controlled infusion (TCI) pump. The appropriate level of sedation was 65 to 80 points on BIS. The adjunctive sedatives (eg, fentanyl, midazolam) was at the discretion of the anesthesia team.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: General Anesthesia
Description: Induction was done with propofol (2 mg/kg) , cis-atracurium (0.15 mg/kg) , and fentanyl (5μg/kg). After orotracheal intubation, general anesthesia was maintained with sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min) and repetitive doses of 0.1mg atracurium per kilogram were administered. After the procedure was completed, neostigmine mixed with atropine was used as a reversal agent for the neuromuscular blockade, and the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Induction Without Neuromuscular Blockade
Description: Anaesthesia was induced with propofol (2 mg/kg), remifentanil(3 ug/kg) and 2% lidocaine (1 mg/kg). Nasotracheal intubation was performed 60 s after the administration. After intubation, general anesthesia was sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min). After the procedure was completed, the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
Study: NCT00593879

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mecamylamine
Description: 2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
Study: NCT01914835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Chess
Description: The Motivational Chess (MC) combines Motivational Interviewing with chess game. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of chess practice and 5 hours of motivational interviewing).~The Active Control (AC) group consists of ten structured activities using cardboard, paper, crayons, among others. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of recreational activities and 5 hours of information about basic cognitive functions).
Study: NCT02579876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viaskin Milk 500 mcg
Description: Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
Study: NCT00593879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Description: 2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
Study: NCT04738279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Continuous Remote Patient Monitoring
Description: Continuous remote patient monitoring will consist of continuous collection of physiological data and patient status through a non-invasive wearable solution, connected to a structured cascading escalation management pathway

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Continuous Remote Patient Monitoring
Description: Continuous remote patient monitoring will consist of continuous collection of physiological data and patient status through a non-invasive wearable solution, connected to a structured cascading escalation management pathway

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
Description: Survey and qualitative interviewing of participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
Description: Survey and qualitative interviewing of participants
Study: NCT02243020

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus Nerve Stimulation (VNS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Study: NCT01593527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: Canakinumab 150 mg s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinelone acetonide
Description: Triamcinelone acetonide 40 mg i.m.
Study: NCT01201746

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Delayed treatment
Description: Scaling, Root Planing and oral hygiene instruction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Description: Scaling, root planning and oral hygiene instructions
Study: NCT03972982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simplified intensive insulin therapy regimen
Description: Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used. Wearable devices and smart apps will be used for lifestyle modification.
Study: NCT03728348

Intervention type: DIAGNOSTIC_TEST
Intervention: mt-sDNA screening test
Description: Stool samples will be collected by the subject for the mt-sDNA screening test.

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Subjects will undergo a screening colonoscopy.
Study: NCT02587390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 900 mg
Description: 3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
Study: NCT03972982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Short-term Intensive insulin therapy
Description: Short-term continuous subcutaneous insulin infusion will be initiate to maitain near normoglycemica for 2 weeks, then patients will be ordinarily follow-up
Study: NCT02289209

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reirradiation
Description: Reirradiation 1.2 GY BID 5 days a week for 5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued once every 3 weeks until 3 months post completion of reirradiation. Further continuation of MK-3475 will be determined by response evaluation at 3 months post completion of reirradiation
Study: NCT03410381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application EMMA
Description: Emma proposes four types of assessments during 6 months:1) 5 times a day during 3 days, every month (5 minutes): patients can assess their emotions, their thoughts, their behavior and their occurrence context. 2) Weekly (7 minutes): consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends, and their quality of life.3) Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.4) Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help. They can contact a relative or call the psychiatric emergency service directly by clicking on a button.
Study: NCT01170364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: 1 week of active sibutramine (15mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: 1 week of active sibutramine (15mg)
Study: NCT02579876

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Viaskin Placebo
Description: Biological: Viaskin Placebo Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
Study: NCT03369275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
Description: Cryopreserved Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
Study: NCT02587390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Description: 2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
Study: NCT03369275

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, with excipients, will be administered intravenously.
Study: NCT01501708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofugin based combination therapy
Description: Caspofungin: 70 mg on the ﬁrst day of therapy, followed by 50 mg q.d.~* All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.~* In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given.
Study: NCT01821742

Intervention type: OTHER
Intervention: Ultrasound cardiac output measurement
Study: NCT02884297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast agent: SonoVue®.
Description: SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
Study: NCT04402866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-0903
Description: Study Drug to be administered by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-0903
Description: Study Drug to be administered by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-0903
Description: Study Drug to be administered by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-0903
Description: Study Drug to be administered by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to be administered by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to be administered by inhalation
Study: NCT01170364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 weeks of placebo
Study: NCT02587390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 80 mg
Description: 2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
Study: NCT02896062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep-coaching
Description: Sleep-coaching with elements of cognitive behavioral therapy for insomnia and general information about sleep

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sleep-coaching
Description: Sleep-coaching with elements of cognitive behavioral therapy for insomnia and general information about sleep
Study: NCT02166424

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 polyunsaturated fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Study: NCT01102244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobradex ST
Description: tobramycin / dexamethasone ophthalmic suspension 0.3%/0.05% 1 drop 4 times daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azasite
Description: azithromycin 1% 1 drop twice daily for 2 days, then once daily for 12 days
Study: NCT01107860

Intervention type: DEVICE
Intervention: Computed Tomography
Description: In Group I, fifty CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.

Intervention type: DEVICE
Intervention: Computed Tomography
Description: In Group II , at least three hundred and fifty (350) study participants, who require diagnostic evaluation of the breast will undergo a breast CBCT . These subjects may be referred for biopsy as a result of a finding from a mammogram, ultrasound, MRI, or clinical exam.
Study: NCT00815295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase 1 - Dose level 1 : Sorafenib will be given 200 mg twice daily oral, Phase 1 - Dose level 2 : Sorafenib will be given 400 mg twice daily oral, Phase 2 : Sorafenib will be given at the maximum tolerated dose from Phase 1
Study: NCT03366480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABTL0812 in combination with paclitaxel and carboplatin
Description: ABTL0812 in combination with paclitaxel and carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABTL0812 in combination with paclitaxel and carboplatin
Description: ABTL0812 in combination with paclitaxel and carboplatin.
Study: NCT04638764

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic interval training combined with high intensity resistance training
Description: Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 70 %- 80 % of one repetition maximum (1-RM)).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic interval training combined with low intensity resistance training
Description: Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 30 %- 40 % 1-RM).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic interval training
Description: Patients enrolled in arm of the study will perform 12 weeks of aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing).
Study: NCT00256269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 40 mg/m2 IV over 60 minutes Every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days
Study: NCT03788031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acuity training
Description: The intervention will be a vision therapy. On each trial, a properly oriented stimulus will be presented randomly at one of the four locations on a flat monitor screen. The visual task is to identify the location of the stimulus.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acuity training
Description: The intervention will be a vision therapy. On each trial, a properly oriented stimulus will be presented randomly at one of the four locations on a flat monitor screen. The visual task is to identify the location of the stimulus.
Study: NCT02855190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-citrate and 18F-FDG PET scans
Description: 68Ga-citrate and 18F-FDG PET/CT or PET/MR scans before operations
Study: NCT03788031

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Occlusion therapy
Description: Participants will be required to patch the good eye for 20 days, 1 hour per day.
Study: NCT04371484

Intervention type: OTHER
Intervention: ICD-10
Description: A collection of ICD-10 codes used within the PMSI that relate to physical abuse.
Study: NCT05072691

Intervention type: DIAGNOSTIC_TEST
Intervention: CSF immunoglobulin (Ig) free light chains (FLC) dosage
Description: CSF immunoglobulin (Ig) free light chains (FLC) dosage in the peripheral blood and cerebrospinal fluid.

Intervention type: DIAGNOSTIC_TEST
Intervention: CSF immunoglobulin (Ig) free light chains (FLC) dosage
Description: CSF immunoglobulin (Ig) free light chains (FLC) dosage in the peripheral blood and cerebrospinal fluid.

Intervention type: DIAGNOSTIC_TEST
Intervention: CSF immunoglobulin (Ig) free light chains (FLC) dosage
Description: CSF immunoglobulin (Ig) free light chains (FLC) dosage in the peripheral blood and cerebrospinal fluid.
Study: NCT02087046

Intervention type: DEVICE
Group type: OTHER
Intervention: ANS Totally Implantable Deep Brain Stimulation System
Description: ANS Totally Implantable Deep Brain Stimulation System will be implanted in the VIM nucleus of the thalamus
Study: NCT00815295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.
Study: NCT02144064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
Study: NCT00917579

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: A single 10 mg dose of marketed 10 mg atorvastatin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: A single 10 mg dose of new formulation of 10 mg atorvastatin
Study: NCT02404597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICOM (non-invasive cardiac output monitor)
Description: The non-invasive cardiac output monitor (NICOM) will be used to tailor fluid management to optimize resuscitation if the patient has an episode of hypotension (defined as systolic blood pressure \<100 or mean arterial pressure \<65). NICOM consists of two electrodes placed on the patient's chest and back and uses bioreactance technology to transduce signals to compute hemodynamic parameters on an associated monitor.~The electrodes will remain on the patient for twenty minutes. Once the electrodes are in place the patient's leg will be raised to 45 degrees and the monitor to which the electrodes are attached will generate a number that reflects stroke volume of the heart. The electrodes will be removed once this number is determined.
Study: NCT00063128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: * Administer subcutaneous regular human insulin 30 to 60 minutes before meals, or administer insulin lispro within 15 minutes before meals.~* Inject into abdomen only.
Study: NCT02692326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyclic parenteral nutrition
Description: Cyclic parenteral nutrition was provided according to a method described by Longhurst et al. Patients were initially cycled of PN for 1 hour per day with increased rate of 1 hour with a maximum time out of PN of 4 hours for preterm babies \< 37 weeks GA and 6 hours for term newborns. Glucose was monitored at half the time without PN to detect the hypoglycemia.
Study: NCT00754338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcon Opti-Free® RepleniSH® with Supraclens®
Description: Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcon Opti-Free® RepleniSH® with Supraclens®
Description: Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
Study: NCT00063128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human insulin inhalation powder (HIIP)
Description: * Administer HIIP within 15 minutes before meals.~* Administer doses in one-capsule increments equivalent to approximately 2 IU or 6 IU of subcutaneous insulin.~* Target treatment goals during the treatment sequence are the same as for patients using preprandial injectable insulin
Study: NCT04153253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection [Eylea]
Description: Three monthly based intravitreal injections were given followed by PRP if the hemorrhage was sufficiently cleared.Intravitreal injection was done in sterile operating room, after sterilization and toweling with application of sterile speculum, Betadine 5% drops was instilled into the conjunctiva and kept for two minutes followed by wash with balanced salt solution. Injection of 2mg /0.05m aflibercept was given 4 mm from the limbus in phakic eyes and 3.5 mm in pseudophakic with compression by sterile cotton tip on the site of injection, Paracentesis was done in cases of very high IOP following injection. At the end of procedure check of visual acuity was done (to be at least light perception).~PRP was done if the hemorrhage is sufficiently cleared after the third injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Was done under local peribulbar anesthesia. After sterilization and toweling, wash with diluted betadine 5% was done. Insertion of three 23 valved cannulas beginning with the lower temporal one for infusion, clearance of anterior vitreous was done followed by core vitrectomy, peripheral vitrectomy , removal of posterior hyaloid aided by triamcinolone staining , trimming and removal of any vascular epicenters followed by vitreous base shaving with 360 scleral indentation, endolaser treatment was done for all eyes followed by fluid air exchange, 20% SF6 was used only if there is active significant bleeding during surgery or if there is intraoperative retinal tears, removal of cannulas was done at the end of surgery. All eyes received combination of topical steroid and antibiotic eye drops as postoperative treatment.
Study: NCT01188707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat and Erlotinib
Description: The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.~When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.~3 patients will be treated at each dose level.
Study: NCT01549288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified Atkins diet
Description: Carbohydrate restricted to 10 g/day (18-36 months) and 5 g/day (9-18 months), fat intake encouraged, proteins unrestricted

Intervention type: OTHER
Group type: OTHER
Intervention: no dietetic input
Description: continuation of anti-epileptic medication without any dietetic input